Stonebranch Introduces Universal Portal to Expand Enterprise-Wide Automation Access
Stonebranch, a leading provider of service orchestration and automation solutions, today announced the launch of Universal Portal. This new solution empowers end-users of any skill level with simple and intuitive self-service automation from anywhere on any device.
As an extension of Universal Automation Center (UAC), Universal Portal offers an alternative method to access automation processes within UAC. This solution enables citizen automators — from developers to business users — to independently initiate and manage their own workflows. Offering automation-as-a-service to the workforce reduces reliance on central IT and accelerates time-sensitive operations.
“With Universal Portal, we're making automation more accessible than ever,” said Giuseppe Damiani, Stonebranch CEO. “Enterprises can now extend the power of UAC to a wider range of users, increasing efficiency while reducing IT workload.”
Key Benefits of the Universal Portal
- Self-Service Access: Users of any skill level gain role-based access to automation without IT intervention.
- User-Friendly Design: A simplified interface designed for fast adoption and ease of use.
- On-the-Go Availability: Universal Portal features a responsive web-based design that works from any device, wherever you are.
- Actionable Insights: Make critical data instantly operational within the portal itself.
By decentralizing automation capabilities, Universal Portal helps organizations scale their automation programs efficiently, driving productivity across IT and business teams alike.
Resources to Learn More:
For a demo or more details, visit stonebranch.com.
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Center, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402353310/en/
Contacts
Scott Davis
Chief Marketing Officer
Stonebranch
scott.davis@stonebranch.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Geoquip Marine Secures €100million Bond to Accelerate Fleet Enhancements and Strategic Growth4.4.2025 10:00:00 EEST | Press release
Geoquip Marine (Geoquip), a global leader in offshore geotechnical solutions and a Njord Partners portfolio company, is pleased to announce today it has successfully closed a €100million bond offering. This bond issuance significantly improves the Company’s cash balance, supports its continued growth, and is seen as a significant step in the Company’s ongoing maturation and development. The bond was placed after a successful roadshow with investors and will be used to advance key strategic initiatives. The immediate use of proceeds will be allocated between the repayment of existing debt and funding for two transformational projects: The Geoquip Silvretta: As announced in December, Geoquip Silvretta is currently in a shipyard in Norway undergoing work to create a state-of-the-art geotechnical services platform for the offshore energy sector. The vessel is on track to start operations in the first half of 2025. The Geoquip Elena: The Company is preparing to install a rig on Geoquip Elen
SES Announces Annual General Meeting Voting Results4.4.2025 09:50:00 EEST | Press release
SES S.A. (“SES” or the “Company”) held the Company’s Annual General Meeting (“AGM”) at its headquarters in Betzdorf, Luxembourg, yesterday. The shareholders have voted all resolutions in accordance with the recommendations made by SES’s Board of Directors, notably the company’s 2024 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total amount includes the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) already paid to shareholders on 17 October 2024. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on 17 April 2025. Also as recommended by the Board of Directors, the shareholders approved the appointments of Mrs Ellen Lord and Mr John Shaw to the Board of Directors and the non-binding agenda item received from Atlas Infrastructure Partners regarding capital returns. “The outcome of the AGM is the result of SES’s ongoing commitment to productive shareholder engagement, ensur
ENHERTU ® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy4.4.2025 09:00:00 EEST | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#
Western Union Offers Zero-Fee International Money Transfers to Myanmar4.4.2025 04:00:00 EEST | Press release
In response to the devastating earthquake that recently struck Myanmar, Western Union today announced that it is offering consumers around the world zero-fee international money transfers1 to the country. Effective immediately until midnight, 00:00 Myanmar Standard Time on 10 April 2025, individuals can send funds to Myanmar via WesternUnion.com or the Western Union mobile app, ensuring families can provide crucial support to their loved ones during this time of urgent need. Western Union remains committed to providing support during times of crisis, offering zero-fee transfers whenever possible to help communities in need. Money transfers sent to Myanmar will be: Available for payout into bank accounts. Available for payout into select mobile wallets Available for payouts incash at Agent locations2 “Our thoughts are with the people of Myanmar during this incredibly difficult time,” said Atish Shrestha, Western Union’s Regional Director for Indochina, South Korea and Taiwan, Western Un
Clean Tech Leader Aymium Defeats Stora Enso at European Patent Office Boards of Appeal4.4.2025 01:07:00 EEST | Press release
Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for renewable battery applications. In its written opinion, the Boards of Appeal of the European Patent Office found Stora Enso's arguments brought before the board “not convincing” and agreed that a clarifying amendment to the claims did not extend the scope of protection of the patent. The ruling further affirms Aymium's position as the global leader in biocarbon materials for battery applications. Beyond the present ruling, Aymium owns a portfolio of more than 600 patents relating to biocarbon materials, compositions and manufacturing methods, including many specifically relevant to battery materials, and is the dominant global innovator regarding biocarbon materials. The ruling, combined with Aymium's massive patent portfolio, calls into question the ability of Stora Enso to produce bio-based ba
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom